Who was studied?
Mice with bilateral subcutaneous MC38 colon tumors.
What does the publication report?
Compared with control, PRaG reduced tumor size on both sides and granulocytic suppressor cells in non-irradiated tumors, while increasing cytokine production by CD8+ T cells in tumor-draining lymph nodes.
Safety findings
This animal report does not evaluate clinical toxicity.
How should we interpret it?
A preprint without established journal peer review. Experimental immune changes cannot be treated as evidence of patient benefit.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Study on the anti-tumor effect of PRaG therapy in colon cancer tumor model · DOI: 10.12383/SciencepaperOnline.202404.0076
Related publications from the same research program
- Mechanistic Study of the Anti-Tumor Effects of PRaG Therapy in a Mouse Colorectal Cancer Tumor Model
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.